Cargando…

A unique tolerizing dendritic cell phenotype induced by the synthetic triterpenoid CDDO-DFPA (RTA-408) is protective against EAE

Tolerogenic dendritic cells (DCs) have emerged as relevant clinical targets for the treatment of multiple sclerosis and other autoimmune disorders. However, the pathways essential for conferring the tolerizing DC phenotype and optimal methods for their induction remain an intense area of research. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wei, Hsi-Ju, Pareek, Tej K., Liu, Qi, Letterio, John J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5575165/ https://www.ncbi.nlm.nih.gov/pubmed/28851867 http://dx.doi.org/10.1038/s41598-017-06907-4

Ejemplares similares

RTA 408, A Novel Synthetic Triterpenoid with Broad Anticancer and Anti-Inflammatory Activity
por: Probst, Brandon L., et al.
Publicado: (2015)

The synthetic triterpenoids CDDO-TFEA and CDDO-Me, but not CDDO, promote nuclear exclusion of BACH1 impairing its activity
por: Casares, Laura, et al.
Publicado: (2022)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease()
por: Aminzadeh, Mohammad A., et al.
Publicado: (2013)

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors
por: Creelan, Ben C, et al.
Publicado: (2017)

The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease
por: Aminzadeh, Mohammad A., et al.
Publicado: (2014)

CDDO-Me: A Novel Synthetic Triterpenoid for the Treatment of Pancreatic Cancer
por: Deeb, Dorrah, et al.
Publicado: (2010)

Synthesis and Anticancer Activity of CDDO and CDDO-Me, Two Derivatives of Natural Triterpenoids
por: Borella, Rebecca, et al.
Publicado: (2019)

Variable effects of omaveloxolone (RTA408) on primary fibroblasts with mitochondrial defects
por: Zighan, Madleen, et al.
Publicado: (2022)

The Triterpenoid CDDO-Me Inhibits Bleomycin-Induced Lung Inflammation and Fibrosis
por: Kulkarni, Ajit A., et al.
Publicado: (2013)

Topical application of RTA 408 lotion activates Nrf2 in human skin and is well-tolerated by healthy human volunteers
por: Reisman, Scott A., et al.
Publicado: (2015)

Prevention of Prostate Cancer with Oleanane Synthetic Triterpenoid CDDO-Me in the TRAMP Mouse Model of Prostate Cancer
por: Gao, Xiaohua, et al.
Publicado: (2011)

The synthetic triterpenoid CDDO-methyl ester modulates microglial activities, inhibits TNF production, and provides dopaminergic neuroprotection
por: Tran, Thi A, et al.
Publicado: (2008)

Structure of the BTB Domain of Keap1 and Its Interaction with the Triterpenoid Antagonist CDDO
por: Cleasby, Anne, et al.
Publicado: (2014)

Prevention and Treatment of Experimental Estrogen Receptor – Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268
por: Liby, Karen, et al.
Publicado: (2008)

The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling
por: Sun, Xuewu, et al.
Publicado: (2019)

Preclinical evidences toward the use of triterpenoid CDDO-Me for solid cancer prevention and treatment
por: Wang, Yan-Yang, et al.
Publicado: (2014)

A Synthetic Triterpenoid CDDO-Im Inhibits Tumorsphere Formation by Regulating Stem Cell Signaling Pathways in Triple-Negative Breast Cancer
por: So, Jae Young, et al.
Publicado: (2014)

The synthetic triterpenoid, RTA405, increases glomerular filtration rate and reduces angiotensin II-induced contraction of glomerular mesangial cells
por: Ding, Yanfeng, et al.
Publicado: (2012)

Inhibition of Telomerase Activity by Oleanane Triterpenoid CDDO-Me in Pancreatic Cancer Cells is ROS-Dependent
por: Deeb, Dorrah, et al.
Publicado: (2013)

Neuroprotective Effects of the Triterpenoid, CDDO Methyl Amide, a Potent Inducer of Nrf2-Mediated Transcription
por: Yang, Lichuan, et al.
Publicado: (2009)

Telomerase Reverse Transcriptase (TERT) is a Therapeutic Target of Oleanane Triterpenoid CDDO-Me in Prostate Cancer
por: Liu, Yongbo, et al.
Publicado: (2012)

The Nrf2 triterpenoid activator, CDDO-imidazolide, protects kidneys from ischemia reperfusion injury in mice
por: Liu, Manchang, et al.
Publicado: (2013)

The novel triterpenoid RTA 408 protects human retinal pigment epithelial cells against H(2)O(2)-induced cell injury via NF-E2-related factor 2 (Nrf2) activation
por: Liu, Xiaobin, et al.
Publicado: (2015)

RTA-408 Protects Kidney from Ischemia-Reperfusion Injury in Mice via Activating Nrf2 and Downstream GSH Biosynthesis Gene
por: Han, Peng, et al.
Publicado: (2017)

Mechanisms and therapeutic implications of RTA 408, an activator of Nrf2, in subarachnoid hemorrhage–induced delayed cerebral vasospasm and secondary brain injury
por: Tsai, Tai-Hsin, et al.
Publicado: (2020)

The Triterpenoid Nrf2 Activator, CDDO-Me, Decreases Neutrophil Senescence in a Murine Model of Joint Damage
por: Amirova, Kristiana M., et al.
Publicado: (2023)

Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405
por: Probst, Brandon L., et al.
Publicado: (2015)

Oleanane triterpenoid CDDO-Me induces apoptosis in multidrug resistant osteosarcoma cells through inhibition of Stat3 pathway
por: Ryu, Keinosuke, et al.
Publicado: (2010)

The triterpenoid CDDO inhibits expression of matrix metalloproteinase-1, matrix metalloproteinase-13 and Bcl-3 in primary human chondrocytes
por: Elliott, Sarah, et al.
Publicado: (2003)

The Triterpenoid CDDO-Methyl Ester Redirects Macrophage Polarization and Reduces Lung Tumor Burden in a Nrf2-Dependent Manner
por: Moerland, Jessica A., et al.
Publicado: (2023)

Partners in crime: MicroRNA408 and peptide miPEP408 negatively regulate arsenic and low sulfur tolerance
por: Ku, Yee-Shan
Publicado: (2023)

Triterpenoid Dihydro-CDDO-Trifluoroethyl Amide Protects against Maladaptive Cardiac Remodeling and Dysfunction in Mice: A Critical Role of Nrf2
por: Xing, Yifan, et al.
Publicado: (2012)

RTA‐408 protects against propofol‐induced cognitive impairment in neonatal mice via the activation of Nrf2 and the inhibition of NF‐κB p65 nuclear translocation
por: Zhang, Ling, et al.
Publicado: (2020)

The triterpenoid CDDO-imidazolide ameliorates mouse liver ischemia-reperfusion injury through activating the Nrf2/HO-1 pathway enhanced autophagy
por: Xu, Dongwei, et al.
Publicado: (2017)

Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis
por: Pareek, Tej K., et al.
Publicado: (2011)

RTA 408 Inhibits Interleukin-1β-Induced MMP-9 Expression via Suppressing Protein Kinase-Dependent NF-κB and AP-1 Activation in Rat Brain Astrocytes
por: Yang, Chien-Chung, et al.
Publicado: (2019)

Triterpenoid CDDO-Me induces ROS generation and up-regulates cellular levels of antioxidative enzymes without induction of DSBs in human peripheral blood mononuclear cells
por: Beinke, Christina, et al.
Publicado: (2020)

Initial Commissioning Results of the RTA Injector
por: Eylon, S, et al.
Publicado: (1999)

At R407/R408
Publicado: (1974)

Cdk5: An Emerging Kinase in Pain Signaling
por: Pareek, Tej Kumar, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_oco4kaukjnun30fedv6qmbgd6g